Genomic Health, Inc. (NASDAQ:GHDX) COO Frederic Pla sold 1,500 shares of the business’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $65.43, for a total value of $98,145.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Frederic Pla also recently made the following trade(s):

  • On Thursday, August 9th, Frederic Pla sold 5,500 shares of Genomic Health stock. The stock was sold at an average price of $55.93, for a total value of $307,615.00.

Shares of NASDAQ GHDX opened at $65.33 on Friday. Genomic Health, Inc. has a one year low of $26.54 and a one year high of $72.83. The firm has a market cap of $2.52 billion, a PE ratio of 6,533.00 and a beta of 0.45.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.19. Genomic Health had a return on equity of 9.09% and a net margin of 1.18%. The firm had revenue of $95.60 million for the quarter, compared to analysts’ expectations of $92.23 million. During the same quarter in the prior year, the firm earned ($0.08) EPS. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Genomic Health, Inc. will post 0.54 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can lifted its position in shares of Genomic Health by 12.1% during the 3rd quarter. Bank of Montreal Can now owns 38,854 shares of the medical research company’s stock valued at $2,728,000 after buying an additional 4,202 shares during the last quarter. Northern Trust Corp lifted its position in shares of Genomic Health by 4.7% during the 2nd quarter. Northern Trust Corp now owns 282,021 shares of the medical research company’s stock valued at $14,214,000 after buying an additional 12,597 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Genomic Health by 30.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 122,246 shares of the medical research company’s stock valued at $6,161,000 after buying an additional 28,710 shares during the last quarter. Castleark Management LLC purchased a new position in shares of Genomic Health during the 2nd quarter valued at $6,370,000. Finally, Millennium Management LLC lifted its position in shares of Genomic Health by 114.0% during the 2nd quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock valued at $72,891,000 after buying an additional 770,413 shares during the last quarter. 89.33% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have weighed in on GHDX. BidaskClub cut Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Cowen reissued a “hold” rating and issued a $50.00 price objective on shares of Genomic Health in a research report on Monday, August 6th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price objective on shares of Genomic Health in a research report on Friday, August 3rd. Canaccord Genuity boosted their price objective on Genomic Health from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. Finally, TheStreet raised Genomic Health from a “c” rating to a “b-” rating in a research report on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $46.11.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Article: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.